Page 3 - Sun Pharmaceutical Industries Ltd News

India's pharma market gets a lift from rising volumes, not just prices

Chronic therapies and GLP-1 adoption help broaden growth drivers as the market expands over 10 per cent in April and May

Sun Pharma's Unloxcyt posts 50% response rate in skin cancer study

Updated data from the CK-301-101 trial showed durable responses and manageable safety profile in patients with locally advanced cutaneous squamous cell carcinoma

Sun Pharma shares slip post Q4; analysts cautious on near-term upside

In the March quarter, Sun Pharma reported net profit at ₹2,714 crore, as compared to ₹2,150 crore a year ago, up 26.2 per cent year-on-year (Y-o-Y)

Sun Pharma's US generics business remains under pressure in FY26

Innovative medicines business crosses $1 billion milestone as company expands specialty pipeline and bets on Organon acquisition

Sun Pharma posts Q4 profit of ₹2,714 crore on strong specialty drug demand

India's largest drugmaker reported stronger-than-expected quarterly profit as growth in specialty medicines offset weakness in US sales

Q4 results: Sun Pharma, Eicher Motors, and Colgate among 187 on May 22

Q4FY26 company results: Firms including Hindalco Industries, Fortis Healthcare, Torrent Pharmaceuticals, Info Edge (India), and TTK Prestige are also to release their January-March earnings today

Why pharma stocks are emerging as safe bet amid global market turmoil

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Organon deal impact: Sun Pharma surges 16% in 10 days, nears record high

Sun Pharma's acquisition of Organon as a transformational deal, doubling revenue to USD 12 billion with 30 per cent EBITDA margin, analysts.